First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
Status:
Completed
Trial end date:
2018-12-13
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess how safe the study drug is and how well a participant
tolerates it after a single oral (taken by mouth) dose. The study also aims to measure the
concentration of the study drug and its breakdown products after a single dose. Participants
will either get NNC0113-2023 (a new medicine) or placebo (a "dummy medicine similar to the
study medicine but without active ingredients) - which treatment any participant gets is
decided by chance. Participants will get one dose (can be one or two tablets) of study
medicine. The study will last for about 65 days. Participants will have 10 scheduled site
visits with the study physician or study staff at the study centre. For one of the visits,
participants will stay at the research unit for 5 days. At all visits, except the first
information visit, participants will have blood drawn along with other clinical assessments.
Participants cannot take part in this study if participants have any disorder that the doctor
thinks is a health problem. Only healthy men are allowed to take part.